Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
On April 15, 2026, the FDA announced the removal of BPC-157 from its 503A Category 2 list, effective April 22, 2026, because the original nominations were withdrawn
Starting conservatively accounts for this uncertainty
This designation supports proper experimental protocols while maintaining compliance with regulatory requirements for research compound distribution and use
It also explains why the final FDA response matters: the committee did not reach anything close to consensus, and FDAs own scientific review remained negative
The peptide helps promote deep sleep, improving physical recovery and overall well-being
Patient consent An informed consent was obtained from the patient
US$ 24.48
US$ 29.76
US$ 28.92
US$ 20.40
